Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Christopher van Dyck, MD

Professor of Psychiatry, Neurology, and Neuroscience; Director, Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry

Contact Information

Christopher van Dyck, MD

Mailing Address

  • Yale School of Medicine

    One Church Street

    New Haven, CT 06510

    United States

Alzheimer's Disease Research Unit

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Christopher H. van Dyck, MD, is Professor of Psychiatry, Neurology, and Neuroscience; Director of the Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry.

His research focuses on neuroimaging and therapeutic studies of Alzheimer’s disease (AD) and brain aging. His current imaging research utilizes positron emission tomography (PET) to study the beta-amyloid (Aβ) and tau proteins, as well as the synaptic targets SV2A and mGluR5. He and his team are examining the full spectrum of AD, including AD-dementia, the prodromal condition of amnestic Mild Cognitive Impairment (aMCI), and preclinical AD—in individuals at high familial and genetic risk.

He also has extensive experience in the conduct and leadership of therapeutic trials in AD. Since 1991 he has led or participated in approximately 90 clinical trials for AD, including the prodromal or preclinical stages. He currently serves on the Steering and Executive Committees and Co-Chairs the Protocol Evaluation Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). He also serves on the Steering Committees of the Alzheimer's Disease Cooperative Study (ADCS), the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the Alzheimer's Therapeutic Research Institute (ATRI). His research accomplishments have been recognized by receipt of the 1996 Junior Investigator Award of the American Association of Geriatric Psychiatry, the 2005 Compassion and Cure Award of the Alzheimer’s Association, and the 2017 Leader in Advancing Research Award of the Alzheimer’s Association. He has published more than 200 peer-reviewed papers, more than 100 of which pertain to Alzheimer's disease.

Specialized Terms: Alzheimer's disease; Brain aging; Cognitive aging; Pharmacotherapy; Neuroimaging; Genetics

Extensive Research Description

Dopamine Transporter (DAT) Imaging in Aging.

He has used SPECT imaging to demonstrate a 50% loss of DATs over the lifespan and has further shown that this loss of dopamine is associated with the slowing of reaction time that is characteristic of the normal aging process.


The Apolipoprotein E e4 (ApoE e4) Phenotype of AD.
He has combined genetics and neuroimaging to characterize the role of the most common genetic risk factor, ApoE e4, in structural and cognitive changes in AD. He has found that patients who carry the ApoE e4 allele are at greater risk for psychosis and for loss of medial temporal lobe tissue. He is now using the PET ligand [11C]PIB to assess amyloid plaques in asymptomatic first-degree relatives as a function of ApoE e4 genotype.

  • Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects (funded by NIA). The major goal of this project is to test the hypothesis that low doses of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated working memory and executive control functions in healthy elderly subjects.
  • Amyloid Binding In Subjects At Risk For Alzheimer’s Disease (funded by Alzheimer's Association). The major goal of this project is to test the hypothesis that in vivo brain Aß burden as measured using [11C]PIB and PET is increased in healthy subjects with a family history of AD who are homozygous or heterozygous for the ApoE e4 allele compared to subjects who lack this allele.
  • Alzheimer’s Disease Cooperative Study Unit (ADCS, funded by NIA). The major goal of this multicenter consortium is to conduct clinical trial research in Alzheimer’s disease that would not otherwise be conducted by private pharmaceutical corporations. Role: Principal Investigator for Yale Site (PI: Paul Aisen, University of California, San Diego)
  • Alzheimer’s Disease Neuroimaging Initiative (ADNI, funded by NIA) The major goals of this project are to: 1. Develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with Alzheimer’s disease, mild cognitive impairment, and elderly controls. 2. Acquire a generally accessible data repository, which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical cognitive and biomarker data for validation of imaging surrogates. Role: Principal Investigator for Yale Site (PI: University of California, San Francisco)

Coauthors

Research Interests

Aging; Alzheimer Disease; Drug Therapy; Genetics; Neurobiology; Neurology; Psychiatry; Positron-Emission Tomography; Neuroimaging

Research Image

Synaptic density (DVR) in Alzheimer's Disease and Cognitively Normal groups determined by [11C]UCB-J PET.

Coronal sections of average parametric images of DVR for (A) 19 Cognitively Normal participants and (B) 34 Alzheimer's Disease participants. Average images are created after co-registration to a common template. The average parametric PET scans are displayed in pseudocolor representing [11C]UCB-J binding to SV2A (DVR) and overlaid on the Montreal Neurological Institute (MNI) template T1 MRI. Lower DVR in Alzheimer's Disease compared to Cognitively Normal participants was apparent in the medial temporal lobe and throughout the cortex and subcortex.

Selected Publications

Clinical Trials

ConditionsStudy Title
Alzheimer's DiseaseA Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
Alzheimer's DiseaseAHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Aging; Mental Health & Behavioral ResearchA Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Alzheimer's Disease; Diseases of the Nervous SystemSafety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Alzheimer's DiseaseAlzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)
Alzheimer's DiseaseDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)
Edit Profile